290 related articles for article (PubMed ID: 27100627)
1. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
[TBL] [Abstract][Full Text] [Related]
2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
3. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
Ramalingam P; Croce S; McCluggage WG
Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Genestie C; Blanc-Durand F; Auguste A; Pautier P; Dunant A; Scoazec JY; Gouy S; Morice P; Bentivegna E; Maulard A; LeFormal A; Devouassoux-Shisheboran M; Leary A
Br J Cancer; 2020 Feb; 122(4):564-568. PubMed ID: 31844183
[TBL] [Abstract][Full Text] [Related]
5. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
[TBL] [Abstract][Full Text] [Related]
6. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
8. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
[TBL] [Abstract][Full Text] [Related]
9. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
[TBL] [Abstract][Full Text] [Related]
10. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
11. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
Wang L; Tan C; Tu X; Zhang Y; Li X; Chang B
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
[TBL] [Abstract][Full Text] [Related]
12. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
13. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Bailey S; Murray MJ; Witkowski L; Hook E; Hasselblatt M; Crawford R; Foulkes WD; Tischkowitz M; Nicholson JC
Pediatr Blood Cancer; 2015 Apr; 62(4):728-30. PubMed ID: 25307865
[TBL] [Abstract][Full Text] [Related]
14. Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis.
Witkowski L; Goudie C; Foulkes WD; McCluggage WG
Surg Pathol Clin; 2016 Jun; 9(2):215-26. PubMed ID: 27241105
[TBL] [Abstract][Full Text] [Related]
15. Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.
Orlando KA; Douglas AK; Abudu A; Wang Y; Tessier-Cloutier B; Su W; Peters A; Sherman LS; Moore R; Nguyen V; Negri GL; Colborne S; Morin GB; Kommoss F; Lang JD; Hendricks WP; Raupach EA; Pirrotte P; Huntsman DG; Trent JM; Parker JS; Raab JR; Weissman BE
Elife; 2020 Dec; 9():. PubMed ID: 33355532
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
17. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
[TBL] [Abstract][Full Text] [Related]
18. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
[TBL] [Abstract][Full Text] [Related]
20. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Ramos P; Karnezis AN; Hendricks WP; Wang Y; Tembe W; Zismann VL; Legendre C; Liang WS; Russell ML; Craig DW; Farley JH; Monk BJ; Anthony SP; Sekulic A; Cunliffe HE; Huntsman DG; Trent JM
Rare Dis; 2014; 2(1):e967148. PubMed ID: 26942101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]